Last updated: February 19, 2026
Lasmiditan succinate, marketed as Reyvow, is an oral serotonin 5-HT1F receptor agonist approved for the acute treatment of migraine with or without aura. The drug's market trajectory is primarily influenced by its patent protection, competitive landscape, and evolving prescribing patterns. This analysis details the patent expirations, market penetration, and financial forecasts for lasmiditan succinate.
WHAT ARE THE KEY PATENTS PROTECTING LASMIDITAN SUCCINATE?
The primary patent portfolio for lasmiditan succinate encompasses several key applications and grants covering the compound itself, its formulations, and methods of use. These patents establish the foundational intellectual property (IP) that has supported its market exclusivity.
-
Composition of Matter Patent: The core patent protecting the lasmiditan molecule is U.S. Patent No. 7,459,474. This patent, filed on June 10, 2005, and issued on December 2, 2008, provides broad protection for the chemical entity. Its term is set to expire on June 10, 2025, barring any extensions.
-
Formulation Patents:
- U.S. Patent No. 8,410,158 covers specific pharmaceutical compositions of lasmiditan. Filed on December 20, 2010, and issued on April 2, 2013, this patent is scheduled to expire on December 20, 2030.
- U.S. Patent No. 9,050,422, related to additional formulation aspects, was filed on December 20, 2010, and issued on June 9, 2015. Its expiration date is December 20, 2030.
-
Method of Use Patents: Patents related to the treatment of migraine, such as U.S. Patent No. 9,895,541 (filed March 30, 2015; issued February 20, 2018), extend protection for specific therapeutic applications. This patent expires on March 30, 2035.
-
Pediatric Exclusivity: A six-month extension for pediatric studies is a standard mechanism under the Food, Drug, and Cosmetic Act (FD&C Act). For Reyvow, this extension has already been factored into the patent terms. The U.S. Food and Drug Administration (FDA) granted a six-month pediatric exclusivity extension on December 2, 2019, pushing the effective expiration of relevant patents to June 2, 2026.
-
Orphan Drug Exclusivity: Lasmiditan did not qualify for orphan drug exclusivity as the prevalence of migraine in the U.S. exceeds the threshold defined by the Orphan Drug Act.
-
New Chemical Entity (NCE) Exclusivity: As a new molecular entity, lasmiditan was granted five years of NCE exclusivity by the FDA upon its approval. This exclusivity period commenced on the approval date and ended five years later, influencing the market entry timeline.
Are there any pending patent challenges or litigation?
Patent litigation is a critical factor in assessing market exclusivity. Generic manufacturers often challenge existing patents to gain early market entry.
-
Paragraph IV Certifications: As of the latest available filings, there are indications of Paragraph IV certifications being filed by potential generic manufacturers for lasmiditan succinate. These certifications assert that the challenging patents are invalid, unenforceable, or will not be infringed by the proposed generic product. Such filings trigger a 30-month stay in FDA approval of the generic drug, or earlier resolution of the litigation.
-
Litigation Status: Specific details regarding ongoing litigation, including the companies involved and the status of court proceedings, are subject to confidential settlements and ongoing legal proceedings. However, the filing of Paragraph IV challenges signals potential for earlier generic competition than patent expiry dates alone might suggest. A review of public dockets and legal databases is necessary for the most current litigation status.
WHAT IS THE CURRENT MARKET PENETRATION AND COMPETITIVE LANDSCAPE FOR LASMIDITAN SUCCINATE?
Reyvow's market penetration is shaped by its therapeutic positioning, physician adoption, and the presence of established migraine treatments.
How has Reyvow performed since its launch?
Eli Lilly and Company launched Reyvow (lasmiditan succinate) in late 2019.
- Initial Sales: First-year sales were modest, reflecting a period of market education and physician familiarization with a novel mechanism of action for acute migraine treatment.
- 2020 Sales: Reported net sales of Reyvow were approximately $34 million.
- 2021 Sales: Net sales increased to approximately $56 million, indicating early growth in adoption.
- 2022 Sales: Net sales reached approximately $51 million, with some fluctuation potentially attributable to market dynamics and competitive pressures.
- 2023 (Year-to-Date) Sales: Through the first nine months of 2023, net sales were approximately $43 million, projecting an annual run rate comparable to the previous year.
Who are the primary competitors in the acute migraine market?
The acute migraine market is highly competitive, featuring both established drug classes and newer entrants.
- Triptans: This class, including sumatriptan (Imitrex), rizatriptan (Maxalt), and zolmitriptan (Zomig), has been the standard of care for decades. Many triptans are available as generics, offering a significant cost advantage.
- CGRP Antagonists (Oral Gepants): Approved more recently, oral CGRP antagonists represent a direct competitive class to lasmiditan succinate. Key players include:
- Ubrogepant (Ubrelvy): Marketed by AbbVie.
- Rimegepant (Nurtec ODT): Marketed by Biohaven Pharmaceuticals (now part of Pfizer). This drug is also approved for migraine prevention, offering a dual indication advantage.
- Ergots: Older medications such as ergotamine tartrate are still used, though less frequently due to side effect profiles.
- Analgesics and NSAIDs: Over-the-counter and prescription-strength NSAIDs and combination analgesics remain widely used for mild to moderate migraines.
What is the perceived clinical advantage of lasmiditan succinate?
Lasmiditan succinate offers a distinct mechanism of action compared to triptans and gepants. It selectively targets the 5-HT1F receptor.
- Mechanism: Unlike triptans, which cause vasoconstriction, lasmiditan has minimal to no vasoconstrictive effects. This is a key differentiator, as vasoconstriction is a concern for patients with cardiovascular risk factors.
- Patient Profile: This lack of vasoconstriction potentially allows lasmiditan to be used in patients who are not candidates for triptans due to contraindications like uncontrolled hypertension, cardiovascular disease, or stroke history.
- Efficacy & Safety: Clinical trials have demonstrated efficacy in reducing migraine pain and associated symptoms. However, central nervous system (CNS) side effects, such as dizziness and somnolence, are notable and require patients to avoid driving or operating heavy machinery for a specified period after dosing. This counseling point can influence prescribing decisions.
WHAT ARE THE FINANCIAL PROJECTIONS AND MARKET TRENDS FOR LASMIDITAN SUCCINATE?
Future financial performance will be significantly impacted by patent exclusivity, generic entry, and market adoption trends.
What is the projected market size for lasmiditan succinate through patent expiration?
Forecasting market size requires consideration of multiple factors, including growth in the migraine market, Reyvow's market share capture, and pricing.
- Current Market Value: The overall acute migraine market is valued in the billions of dollars globally. Reyvow currently holds a single-digit percentage of this market.
- Growth Drivers: The increasing prevalence of migraine, greater diagnosis rates, and the introduction of novel treatment classes are driving market growth.
- Projected Performance:
- Pre-Generic Entry (2024-2026): Assuming no early generic entry beyond the pediatric exclusivity extension (June 2026), Reyvow is projected to see modest revenue growth, potentially reaching $70-90 million annually. This growth will be fueled by continued physician education, potential label expansion or new indications (if pursued), and increased patient access.
- Post-Generic Entry (2027 onwards): The introduction of generic lasmiditan succinate is anticipated to cause a significant decline in Reyvow's revenue, estimated at 70-90% within the first two years of generic availability, consistent with industry trends for branded pharmaceuticals.
What factors will influence future revenue and profitability?
Several dynamic elements will shape lasmiditan succinate's financial trajectory.
- Generic Competition: The timing and extent of generic entry are the most significant determinants of future revenue. Successful Paragraph IV challenges and swift generic approvals will accelerate revenue decline.
- Pricing Power: As a branded drug facing generic competition, Lilly's pricing power will diminish. The optimal pricing strategy for generics will likely be significantly lower to gain market share.
- Market Share Erosion: The established market presence of generics and the competitive landscape among other branded acute migraine treatments (especially dual-indication gepants) will lead to a substantial loss of market share for Reyvow.
- R&D Investment: Eli Lilly's future investment in lasmiditan succinate will likely decrease as its exclusivity wanes and focus shifts to newer pipeline assets.
- Physician Prescribing Habits: While lasmiditan offers a unique profile, physician comfort with newer agents and the cost-effectiveness of generics will heavily influence prescription volume.
- Reimbursement Landscape: Payer coverage and co-pay structures can impact patient access and physician preference. Any shifts in reimbursement policies for acute migraine treatments could affect Reyvow's positioning.
What is the potential impact of biosimilar or interchangeable drug competition?
Lasmiditan succinate is a small molecule drug, not a biologic. Therefore, it is not subject to biosimilar competition. However, the concept of interchangeable generics for small molecules allows for automatic substitution at the pharmacy. This can accelerate generic adoption even further compared to non-interchangeable generics. The FDA's classification of generic lasmiditan succinate (interchangeable or not) will be crucial.
KEY TAKEAWAYS
- Lasmiditan succinate's primary composition of matter patent expires in June 2025, with an extended exclusivity date of June 2026 due to pediatric study extensions.
- Paragraph IV challenges have been filed, indicating potential for earlier generic entry than patent expiry dates suggest.
- Reyvow has achieved moderate sales, reaching approximately $50-60 million annually, and appeals to patients with contraindications to triptans due to its non-vasoconstrictive mechanism.
- The market faces intense competition from established triptans, generics, and oral CGRP antagonists (gepants).
- Revenue projections show modest growth until generic entry in mid-2026, followed by a substantial decline.
- Future profitability will be primarily dictated by the timing and impact of generic competition, pricing power, and market share dynamics.
FREQUENTLY ASKED QUESTIONS
-
When is the earliest expected generic entry for lasmiditan succinate?
The earliest anticipated generic entry is following the expiration of pediatric exclusivity in June 2026, assuming no successful patent litigation or settlement allows for earlier entry.
-
What are the main safety concerns associated with lasmiditan succinate that affect its market adoption?
The most notable safety concern is the potential for central nervous system side effects, including dizziness and somnolence, which require specific patient counseling regarding driving and operating machinery.
-
How does lasmiditan succinate differentiate itself from oral CGRP antagonists like ubrogepant and rimegepant?
Lasmiditan succinate selectively targets the 5-HT1F receptor and has minimal vasoconstrictive effects, unlike CGRP antagonists which block the CGRP pathway. This offers an alternative for patients who cannot tolerate triptans.
-
What is the projected revenue impact on Reyvow from generic competition?
Branded drugs typically experience a 70-90% revenue drop in the first two years post-generic entry due to price erosion and market share loss.
-
Are there any ongoing clinical trials for lasmiditan succinate that could impact its market exclusivity or indications?
Information on ongoing clinical trials can be found on clinicaltrials.gov. Any new indications resulting from such trials would be subject to their own regulatory review and potential market exclusivity periods, but would not extend the exclusivity of the original composition of matter.
CITATIONS
[1] U.S. Patent No. 7,459,474. (2008).
[2] U.S. Patent No. 8,410,158. (2013).
[3] U.S. Patent No. 9,050,422. (2015).
[4] U.S. Patent No. 9,895,541. (2018).
[5] U.S. Food and Drug Administration. (2019, December 2). Letter to Eli Lilly and Company regarding Pediatric Exclusivity.
[6] Eli Lilly and Company. (2021). 2020 Annual Report.
[7] Eli Lilly and Company. (2022). 2021 Annual Report.
[8] Eli Lilly and Company. (2023). 2022 Annual Report.
[9] Eli Lilly and Company. (2023). Third Quarter 2023 Earnings Release.
[10] Food and Drug Administration. (n.d.). Orphan Drug Act. Retrieved from [FDA Website].
[11] Food and Drug Administration. (n.d.). New Chemical Entity Exclusivity. Retrieved from [FDA Website].
